Andrea Apolo: Very proud of this Clinical Trial of Cabozantinib/Nivolumab published at JCO

Shilpa Gupta shared a post by Andrea Apolo, adding:

“Huge congrats Andrea Apolo, leading this critical work addressing an unmet need in rare GU (genitourinary) tumors!”

Quoting Andrea Apolo‘s post:

“Very proud of this Clinical Trial of Cabozantinib/Nivolumab  and Cabozantinib/ Nivolumab/Ipilimumab published in Journal of Clinical Oncology(JCO), that includes rare GU tumors and  took years to complete but laid the foundation for many future trials in oncology.”

Source: Shilpa Gupta /X and Andrea Apolo/X

 Shilpa Gupta is the Director of Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials.

Andrea Apolo is the Chief of the Bladder Cancer Section of the Genitourinary Malignancies Branch and Director of the Bladder Cancer and Genitourinary Tumors Multidisciplinary Clinic at the National Cancer Institute (USA). Apolo received a 2011 National Institutes of Health Award of Merit, the 2014 Lasker Clinical Research Scholars Program Award, the 2018 National Cancer Institute’s Director’s Award for Clinical Science, the 2018 Advancing Cancer Treatment Award for leadership in genitourinary clinical trial patient access, and the 2020 Arthur S. Flemming Award for leaders who make an impact in public service.